Use of type I and type IV hypersensitivity responses to define the immunopharmacological profile of drugs

Journal of Pharmacological and Toxicological Methods

Volumn 37, Issue 2, 1997, Pages 91-96

  Di Pierro, Francesco ^a   D'Atri, Gaetano ^a   Marcucci, Fabrizio ^a   Leoni, Flavio ^a  

^a Italfarmaco SpA   (Italy)

Author keywords

Anaphylactic shock; Anti anaphylactic drugs; Antiinflammatory drugs; Delayed type and immediate type hypersensitivity reactions; Immunosuppressive drugs

Indexed keywords

CYCLOSPORIN A; DEXAMETHASONE; DEXCHLORPHENIRAMINE; INDOMETACIN; KEYHOLE LIMPET HEMOCYANIN; LEFLUNOMIDE; NALOXONE; TETRAPEPTIDE;

ANAPHYLACTIC SHOCK; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG SCREENING; FEMALE; HYPERSENSITIVITY REACTION; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNIZATION; IMMUNOPHARMACOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION;

ANIMALS; C-REACTIVE PROTEIN; CYCLOSPORINE; DRUG EVALUATION, PRECLINICAL; FEMALE; HYPERSENSITIVITY, DELAYED; HYPERSENSITIVITY, IMMEDIATE; IMMUNOSUPPRESSIVE AGENTS; INDOMETHACIN; ISOXAZOLES; MICE; MICE, INBRED BALB C;

EID: 0030946879     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1056-8719(97)00003-8     Document Type: Article

References (30)

1. Abramson SB, Weissmann G (1989) The mechanisms of action of nonsteroidal antiinflammatory drugs. Arth Rheum 32:1-9.
2. Amir S (1988) Anaphylactic shock: Catecholamine actions in response to opioid antagonist. Prog. Clin Biol Res 264:265-274.
3. Babany G, Morris RE, Babany I, Kates RE (1988) Evaluation of the in vivo dose-response relationship of immunosuppressive drugs using a mouse heart transplant model: application to cyclosporin. J Pharmacol Exp Ther 244:259-262.
4. Bartlett RR, Dimitrjievic M, Mattar T, Zielinski T, Germann T, Rude E, Thones GH, Kuchle CCA, Schorlemmer HU, Bremer E, Finnegan A, Schleyerbach R (1991) Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection. Agents Actions 32:10-21.
5. Borchard RE, Barnes CD, Eltherington LG, (1992) Drug dosage in laboratory animals: A handbook. Boca Raton, Florida: The Telford Press Inc.
6. Bertolini G, Aquino M, Biffi M, d'Atri G, Di Pierro F, Ferrario F, Mascagni P, Somenzi F, Zaliani A, Leoni F (1997) A new rational hypothesis for the pharmacophore of the active metabolite of leflunomide. Submitted to J Med Chem.
7. Cher DJ, Mosmann TR (1987) Two types of murine helper T cell clone. II. Delayed-Type Hypersensitivity is mediated by Th1 clones. J Immunol 138:3688-3694.
8. Cherwinski HM, Cohn RG, Cheung D, Webster DJ, Xu JZ, Caulfield JP, Young JM, Nakano G, Ransom JT (1995a) The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J Pharmacol Exp Ther 275:1043-1049.
9. Cherwinski HM, McCarley D, Schatzman R, Devens B, Ransom JT (1995b) The immunosuppressant leflunomide inhibits lymphocyte progression through cell cycle by a novel mechanism. J Pharmacol Exp Ther 272:460-468.
10. Cupps TR, Fauci AS (1982) Corticosteroid-mediated immunoregulation in man. Immunol Rev 65:133-155.
11. Davis JP, Cain GA, Pitts WJ, Magolda RL, Copeland RA (1996) The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry 35:1270-1273.
12. D'Silva M, Candinas D, Achilleos O, Lee S, Antoniou E, DeRoover A, Germenis A, Stavropoulos C, Buckels J, Mayer D, McMaster P (1995) The immunomodulatory effect of leflunomide in rat cardiac allotransplantation. Transplantation 60:430-437.
13. Einbinder JM, Walzer RA, Nelson CT (1964) The role of the mast cells in anaphylaxis in mouse. J Immunol 93:155-161.
14. Gerkens JF, Shand DG, Flexner C, Nies AS, Oates JA, Data JL (1977) Effect of Indomethacin and aspirin on gastric blood flow and acid secretion. J Pharmacol Exp Ther 203:646-652.
15. Ishizaka T, Ishizaka K (1984) Activation of mast cells for mediator release through IgE receptor. Prog Allergy 34:188-235,
16. Janeway Jr. CA, Travers P (1994) Immunobiology: the immune system in health and disease. Hamden, CT: Garland Publishing and Current Biology Ltd., pp. 1102-1114.
17. Kinet JP (1989) The high affinity receptor for IgE. Curr Opin Immunol 2:499-505.
18. Ogawa T, Inazu M, Gotoh K., Hayashi S (1990) Effects of leflunomide on glomerulonephritis induced by antibasement membrane antibody in rats. Agent Actions 31:321-328.
19. Parnham MJ (1995) Leflunomide: A potential new disease-modifying anti-rheumatic. Exp Opin Invest Drugs 4(8):777-779.
20. Pasternak RD, Wadopian NS, Wright RN, Siminoff P, Gylys JA, Buyniski JP (1987) Disease modifying activity of HWA 486 in rat adjuvant-induced arthritis. Agent Actions 21:241-243.
21. Popovic S, Bartlett RR (1986) Disease modifying activity of HWA 486 on the development of SLE in MRL/1-mice. Agents Actions 19:313-314.
22. Popovic S, Bartlett RR (1987) The use of murine chronic graft versus host (CVGH) disease, a model for systemic lupus erythematosus (SLE), for drug discovery. Agent Actions 21:284-286.
23. Romagnani S (1992) Induction of Th1 and Th2 responses: a key role for the "natural" immune response? Immunol Today 13:379-381.
24. Scheinman RI, Gualberto A, Jewell CM, Cidlowski JA, Baldwin Jr. AS (1995) Characterization of mechanism involved in transrepression of NF-kB by activated glucocorticoid receptors. Mol Cell Biol 15:943-953.
25. Terashita Z, Imura Y, Shino A, Nisikawa K (1987) A lethal role of platelet-activating factor in anaphylactic shock in mice. J Pharmacol Exp Ther 243:378-383.
26. Thienpont D, Vanparijs OF, Raeymaekers AH, Vanderberk J, Demoen JA, Allewijn FT, Marsboom RP, Niemegeers CJ, Schellenkens KH, Janssen PA (1966) Tetramisole (R8299) a new potent broad spectrum anthelmintic. Nature 209:1084-1086.
27. Thoenes GH, Sitter T, Langer KH, Bartlett RR, Schleyerbach R (1989) Leflunomide (HWA 486) inhibits experimental autoimmune tubulointerstitial nephritis in rats. Int J Immunopharmacol 11:921-929.
28. Thomson AW, Starzl TE (1993) New immunosuppressive drugs: mechanistic insight and potential therapeutic advance. Immunol Rev 136:71-98.
29. Tsai MJ, O'Malley BW (1994) Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 63:451-486.
30. Williamson RA, Yea CM, Robson PA, Curnock AP, Gadher S, Hambleton AB, Woodward K, Bruneau JM, Hambleton P, Moss D, Thomson TA, Spinella-Jaegle S, Morand P, Courtin O, Sautes C, Westwood R, Hercend T, Kuo EA, Ruuth E (1995) Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound. J Biol Chem 270:22467-22472.